Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols" or the "Company") hereby informs about the following

**RELEVANT EVENT**

Grifols has earned approval from the U.S. Food and Drug Administration (FDA) for a liquid formulation of its alpha-1 antitrypsin (Prolastin®-C Liquid) as a replacement therapy to treat alpha-1 antitrypsin deficiency, a rare genetic disorder.

The FDA approval culminates an important R&D initiative to create a new product formulation of alpha-1 antitrypsin, whose ready-to-infuse format requires less preparation time and volume for infusion. Until now, the formulation had only been offered in a lyophilized format.

Prolastin®-C Liquid is the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy manufactured in the U.S. This plasma-derived product will be also manufactured at Grifols industrial site in Barcelona, Spain. The approval process for the product has also commenced in Europe.

The commercial launch of the liquid formulation, Prolastin®-C, is scheduled for 2013.

Additionally, on September 15, Grifols received a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to approve Grifols’ VeraSeal®, a product for surgical use in adults. VeraSeal® is a biological sealant composed of fibrinogen and human thrombin used in surgical operations to expedite the healing process.

In Barcelona, on 22 September 2017

Nuria Martín Barnés
Secretary to the Board of Directors